Search Results

The Nichols Advantage™ Chemiluminescence Thyroid Peroxidase Autoantibodies Immunoassay is intended for use on the Nichols Advantage™ Specialty System for the quantitative determination of Thyroid Peroxidase Autoantibodies (TPOAb) in human serum as an aid in the diagnosis and assessment of patients with autoimmune thyroid disease.

The Nichols Advantage™ Anti-TPO is a two-site chemiluminescence assay for use with the Nichols Advantage™ Specialty System

Here's an analysis of the provided text regarding the acceptance criteria and study proving the device meets them, presented in the requested format:

Acceptance Criteria and Device Performance Study

1. Table of Acceptance Criteria and Reported Device Performance

The document does not explicitly state "acceptance criteria" for each performance characteristic. However, by comparing the performance of the new device (Nichols Advantage™ Chemiluminescence Anti-TPO) to the predicate device (Nichols Institute Diagnostics Chemiluminescence Anti-TPO), it can be inferred that the performance of the new device should at least be comparable to or better than the predicate, or meet established laboratory standards for clinical assays. For the purpose of this analysis, the predicate device's performance will be used as a reference point for implicit acceptance.

Note on Sensitivity: The "Sensitivity" listed under "Similarities" (0.5 IU/mL) for the Nichols Advantage™ is lower than the predicate (0.2 IU/mL), meaning the predicate assay can detect lower concentrations. However, both are stated to be "sufficient to measure Anti-TPO autoantibody levels found in patients with autoimmune disease." Therefore, 0.5 IU/mL for the Nichols Advantage™ is still implicitly accepted as meeting clinical needs.

2. Sample Size Used for the Test Set and Data Provenance

The document provides sample sizes for different performance characteristics:

• Intra-Assay & Inter-Assay:
  • For Nichols Advantage™: 20 replicates for each of the three concentration levels tested (low, medium, high).
  • For Predicate Device: 21, 22, or 23 replicates for each concentration level.
• Other characteristics (Recovery, Parallelism, High Dose Hook Effect, Specificity, Method Comparison, Relative Sensitivity, Relative Specificity, Agreement): The specific sample sizes for these tests are not explicitly stated in the provided text.

Data Provenance: The document does not specify the country of origin of the data or whether the studies were retrospective or prospective.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Their Qualifications

This information is not provided in the document. The study appears to be a laboratory performance evaluation of an in-vitro diagnostic device measuring TPO autoantibodies, not an imaging or diagnostic interpretation study requiring expert consensus for ground truth. The "ground truth" for such assays is typically established by reference methods or clinical diagnosis supported by various laboratory and clinical findings.

4. Adjudication Method for the Test Set

Since this is an in-vitro diagnostic device measuring analytes, and not a human-interpreted diagnostic output, an adjudication method (like 2+1 or 3+1) involving human experts is not applicable and therefore, not specified.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

An MRMC study is relevant for diagnostic devices that involve human interpretation of results (e.g., medical imaging). This is an in-vitro diagnostic assay for TPO autoantibodies. Therefore, an MRMC comparative effectiveness study was not performed or is not relevant in this context. The document does not mention any human reader assistance or effect size of AI.

6. Standalone (Algorithm Only Without Human-in-the-Loop Performance) Study

This device is an automated chemiluminescence immunoassay system. Its performance, as described in the "Performance Characteristics" section, represents the standalone (algorithm/system only without human-in-the-loop performance). The results presented (precision, recovery, specificity, sensitivity, etc.) reflect the intrinsic analytical performance of the device without human interpretation or intervention in the measurement process itself, beyond standard laboratory procedures for operating the instrument and handling samples.

7. Type of Ground Truth Used

For an immunoassay like this, the ground truth is typically established by:

• Reference materials/known concentrations: For analytical performance characteristics like precision, recovery, and linearity.
• Clinical Diagnosis/Known Patient Status: For determining relative sensitivity, specificity, and agreement, where TPOAb levels are correlated with a clinical diagnosis of autoimmune thyroid disease.
• Correlation with a predicate device or established method: For method comparison studies.

The document mentions "Preliminary Reference Range: Normal < 2.0 IU/mL," implying a comparison against clinically defined normal and abnormal populations, but it does not explicitly detail how these clinical ground truths were established (e.g., biopsy, long-term follow-up, other clinical markers).

8. Sample Size for the Training Set

The document describes an assay. It does not mention any "training set" in the context of machine learning or AI models. The development and calibration of the assay would likely involve numerous samples, but these are not explicitly referred to as a "training set" in this context.

9. How the Ground Truth for the Training Set Was Established

As there is no mention of a "training set" in the context of an AI/ML model, this information is not applicable and therefore, not provided. The ground truth for the assay's development and validation would have been established through a combination of well-characterized samples, reference standards, and clinical samples with known diagnoses, as is standard practice for IVDs.

Ask a specific question about this device